The trial met its primary outcome of improvement in the distance pulmonary arterial hypertension patients could achieve during a six-minute walk. Compared to a placebo, seven other endpoints were also statistically significant.
About 40,000 people in the U.S. are diagnosed with pulmonary arterial hypertension, which is a progressive, life-threatening disease, Merck said.
Sotatercept was part of the drugmaker’s $11.5 billion acquisition of Acceleron Pharma in November 2021.
Based on the results, Merck Research Laboratories President Dean Li said, “We are moving with urgency on our regulatory applications to bring this investigational therapy to these patients.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
